Baxter Announced That Vantive Will Be The Name Of The Company's Proposed Spinoff Of Its Renal Care And Acute Therapies Businesses; Vantive Is Expected To Launch As An Independent, Publicly Traded Company By July 2024 Or Earlier
Portfolio Pulse from Benzinga Newsdesk
Baxter International Inc. has announced that its proposed spinoff of its renal care and acute therapies businesses will be named Vantive. The spinoff is expected to launch as an independent, publicly traded company by July 2024 or earlier.
July 25, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Baxter's decision to spinoff its renal care and acute therapies businesses into a new entity named Vantive could potentially impact its stock in the short term.
The announcement of a spinoff often leads to uncertainty among investors, which can cause stock price volatility. However, the impact on Baxter's stock will depend on how the market perceives the potential of the new entity, Vantive, and its effect on Baxter's overall business.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100